acquired
Stage
3
Investors
About
Corvidia Therapeutics was a biopharmaceutical company that developed ziltivekimab, an anti-IL-6 ligand monoclonal antibody aimed at reducing inflammation-driven cardiovascular risk in patients with chronic kidney disease. The company was acquired by Novo Nordisk (stage: acquired).
Explore Corvidia Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.